Finance Brief · For the Chief Financial Officer
Most pharma AI programs don't fail on the technology. They fail on investment logic. These are the five questions finance actually asks, and evidence infrastructure, powered by the Provenance Neural Engine (PNE), is built to pass each one.
A great demo still has to clear one gate: finance. And finance doesn't ask can it work? It asks which initiatives create measurable value, in what sequence, at what cost, and defended against everything else competing for the same capital. Most AI cases were built to prove potential, not to survive that question. The five below are the test.
Where programs stall
A model can predict beautifully and change no action. Accuracy alone creates no return if the workflow and the decision don't move with it.
How evidence infrastructure answers
Evidence infrastructure grounds every AI output in a governed record of facts and their provenance, so insight lands as an action a team can trust (a field call, a submission, a safety signal), not an analysis no one can stand behind.
Where programs stall
A blended "AI ROI" hides weak initiatives inside a strong average, so finance can't prioritize, sequence, or defend the number to a board.
How evidence infrastructure answers
Evidence infrastructure is one initiative that makes every application built on it cheaper, safer, and audit-ready by default, improving the whole portfolio's numbers, not adding one more line to defend.
Where programs stall
Time saved is not value until it's redeployed, removed, or converted to throughput. Most cases stop at "hours saved."
How evidence infrastructure answers
Provenance captured in place makes recovered capacity auditable and re-deployable, not merely asserted. Time "saved" on work whose evidence chain is later rebuilt by hand isn't saved; it's a cost deferred.
Where programs stall
Cases count licenses and build, and understate the rest: integration, validation, monitoring, security, and the governance a regulated deployment can't skip. And there is a cost few cases price at all: company data pasted into public AI tools that may train on it, and home-built tools whose numbers can't be traced back to a source.
How evidence infrastructure answers
Governance is built into evidence infrastructure, not added on. And because the PNE supplies the grounding underneath, the reasoning model on top can be smaller, which is projected to lower TCO.
Where programs stall
"Do nothing" is treated as the free baseline. It isn't: the real choice is build the capability now or accept a weaker position later.
How evidence infrastructure answers
Regulators are already writing it down: the FDA/EMA joint principles (Jan 2026) call for data governance and documentation across the AI life cycle, and the EU AI Act's record-keeping duties for high-risk AI apply from December 2027 (August 2028 for AI built into regulated products). Latency and data-readiness costs compound from today; the early foundation is the one competitors can't quickly close.
Provenance is expected
The FDA/EMA joint AI principles (Jan 2026) set the expectation for data governance and documentation. EU AI Act high-risk obligations, including record-keeping, apply from Dec 2027, or Aug 2028 for AI in regulated products.
FDA/EMA 2026 · EU AI Act fda.govOne re-allocatable wallet
The architecture deficit, the missing provenance layer beneath your AI, drains R&D productivity, decision latency, compliance exposure, and knowledge loss at once. Evidence infrastructure re-allocates the tax across all four.
ScientixAI analysisMetered OpEx elevates CFO earlier
The shift from seat-based software to metered token consumption elevates the CFO earlier in the AI decision: metered OpEx is part of the full cost at scale, and the foundation-grounded architecture lowers that cost structurally.
ScientixAI analysisProvenance Neural Engine™ is a trademark of Scientix.ai Inc. The "CFO test" is a market framing of capital-allocation scrutiny; supporting figures are ScientixAI analysis at their stated confidence. Regulatory dates per the FDA/EMA joint AI principles (2026) and the EU AI Act as amended by Regulation (EU) 2026/1744.
Provenance. Every board-defensible-AI framework asks the five questions above, and stops. Provenance is what turns the answers from claims into something a CFO, and a regulator, can inspect: the auditable link from a machine's output back to the evidence behind it. It's what evidence infrastructure supplies, and what the passing case is built on.
Start with the first engagement. We'll run a structured workshop to build the finance-grade model with you: initiative-level economics, honest costs at scale, and the cost of delay. The case your CFO will actually fund, and the foundation that makes it defensible.